Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A new study reveals how breast cancer cells become desensitized to lapatinib, a common cancer drug, by turning FOXO into an oncogene c-Myc. The researchers hope to develop new tools to fix this adaptation pathway and improve therapy for HER2+ breast cancer.
Researchers discovered that mice lacking both Pten and Shp2 enzymes are prone to lethal anemia, which can occur even if they lack one of the enzymes alone. This finding suggests that genomic screening before treatment may help prevent anemia in cancer patients.
Researchers at Indiana University have discovered how cancer-induced bone destruction causes skeletal muscle weakness. Inhibiting TGF-β improved muscle function in mouse models of human cancers.
Researchers at the Walter and Eliza Hall Institute have created a 3D image of cancer protein Trib1, revealing its role in controlling protein levels within cells. The finding could lead to the development of new drugs to treat cancers such as leukemia.
Researchers at Georgetown University Medical Center have discovered a compound that effectively controls the growth of EWS-FLI1-driven cancer cells in mice. The study found that YK-4-279 significantly reduced leukemia cell numbers and improved mouse health, suggesting potential as a therapeutic agent for various cancers.
Discussing a menu of reasonable treatment options with patients can improve patient compliance and health outcomes. Physicians often present only one option, but a partnership approach that includes patient preference can make a real difference.
Researchers at the University of Pennsylvania School of Medicine identified a previously unknown genomic landscape in Sezary syndrome, a rare and aggressive leukemia. The study reveals recurrent loss-of-function mutations in genes regulating epigenetic pathways, including ARID1A, which occurred in over 40% of the genome studied.
Researchers describe a case of a 53-yr-old male with early T-cell precursor leukemia who achieved complete remission after treatment with the NOTCH inhibitor BMS-906024. Genetic and epigenetic analysis revealed that the patient's cancer was driven by hyperactive NOTCH1 signaling, which was successfully targeted by GSI treatment.
A new pan-Canadian Dream Team, led by Tak W. Mak and Samuel Aparicio, will research novel approaches to treating aggressive breast cancers. The team aims to develop new therapies targeting genetic instability in tumor cells.
Researchers have discovered a new approach to understanding cancer mechanisms, biomarkers, and treatments using RNA editing events. The study, published in Cancer Cell, found that specific RNA editing processes could selectively affect drug sensitivity and may lead to the development of targeted therapies.
A Phase 2 clinical trial found that gene therapy VB-111 increased overall survival to 15 months, compared to 8 months for those receiving chemotherapy Avastin alone. The therapy effectively starves tumors by blocking new blood vessel growth and is safe and well-tolerated.
Researchers at NYU Langone Health found that GANT61 increases myelin production by 50% and recruits neural stem cells to repair damaged areas of the brain. The treatment also improves symptoms in mice with multiple sclerosis, including paralysis and leg weakness.
A new study led by UCSF scientist Neal Benowitz found that reducing nicotine levels in cigarettes can substantially decrease tobacco dependence without increasing inhalation. Smokers who reduced cigarette intake reported attempts to quit twice as often and had lower cravings compared to those smoking regular cigarettes.
Researchers are investigating two new avenues for detection and treatment of advanced prostate cancer, focusing on biochemical reactions downstream of the androgen receptor. By targeting the metabolism of cancer cells, they aim to bypass ineffective drugs and develop new therapies.
A new study by the University of Copenhagen and Cancer Research UK shows that targeting fibroblasts can block cancer cell movement, trapping them in healthy tissue. The research uses a drug that targets PHD2, an inhibitor currently in clinical trials for anaemia.
Researchers have developed a technique to coat anticancer drugs in membranes made from a patient's own platelets, allowing the drugs to target both primary tumors and circulating tumor cells. This method can prolong drug circulation time up to 30 hours, increasing effectiveness.
A recent study by researchers found that FDA's 'breakthrough' designation significantly increases the percentage of people who rate a drug as effective and believe in its strong evidence. The study suggests that neutral terms with clear explanations may help consumers make more accurate judgments about these drugs.
The NCI has renewed a five-year, $13 million grant to support joint research projects between San Diego State University and UC San Diego Moores Cancer Center. The partnership aims to address cancer health care disparities among Hispanic/Latinos in the region, with a focus on innovative research and community outreach.
A phase 3 clinical trial found that immunotherapy drug nivolumab improved overall survival and reduced toxicities compared to chemotherapy drug docetaxel for patients with non-squamous non-small cell lung cancer. The results suggest that nivolumab is a promising option for patients whose lung cancer progresses after initial treatment.
A study of 129 children born after prenatal exposure to cancer treatment found normal mental and heart function, contradicting fears that chemotherapy would harm fetal development. However, premature birth was more frequent among these children than in the general population, suggesting avoiding prematurity is key.
A new clinical trial has found that cabozantinib, a second-line therapy, controls the growth of advanced kidney cancer more effectively than everolimus. The results show improved progression-free survival and lower tumor growth rates, indicating potential for prolonged survival.
Researchers found that the combination therapy improved progression-free survival across various sub-groups, including those with poor prognostic factors. The study also showed similar efficacy regardless of BRAF mutation status and disease stage.
The ESMO Global Opioid Policy Initiative reveals disparities in opioid access across the globe, with the Middle East, Latin America, and Asia showing limited access to essential pain relieving medication. The addition of new Designated Centres brings polices tailored to patient needs, promoting a multidisciplinary approach to cancer care.
Research highlights significant disparities in cancer care among migrants and refugees, with lower rates of early diagnosis and treatment. The European Society for Medical Oncology calls for policy changes to address these disparities and improve access to quality cancer care.
A new study reveals that brain metastases carry distinct genetic profiles compared to primary tumors, suggesting divergent evolutionary pathways and potential sensitivity to targeted therapy drugs. The research identifies clinically significant mutations in over half of patients' brain metastases.
Researchers at the University of Texas MD Anderson Cancer Center demonstrated a significant median overall survival benefit with nivolumab, increasing it to 25 months compared to 19.6 months for everolimus. The study also showed a higher objective response rate and fewer treatment-related adverse events with nivolumab.
Results from the METEOR trial show that cabozantinib improves progression-free and overall survival in patients with advanced clear cell kidney cancer, with a median progression-free survival of 7.4 months compared to 3.8 months for everolimus.
Researchers found that combining antidepressants with blood thinners increases autophagy in cancer cells, causing them to die. This combination therapy doubled the lifespan of mice with early-stage brain cancer, but further study is needed to confirm its effectiveness.
Researchers have discovered that combining tricyclic antidepressants with anticoagulant drugs can slow down glioma tumors in mice by causing excessive autophagy. The study, published in Cancer Cell, found that the combination therapy doubled the lifespan of mice with gliomas.
Researchers have discovered that a class of experimental drugs already in clinical trials can help the body's immune system fight cancer. The drugs target a protein called Focal Adhesion Kinase (FAK), which is often overproduced in tumors and enables them to evade the immune system.
Researchers have identified a molecular pathway that explains how tamoxifen-resistant breast cancer cells develop. The 'feedback loop' involves the HOXB7 protein, which helps activate genes that promote cancer growth. Targeting MYC protein, which is involved in this pathway, may lead to new treatments for tamoxifen-resistant cancers.
A new study published in the Journal of Oncology Practice found that patients participating in stage III renal cell cancer drug trials are often younger and healthier than those who ultimately receive the drugs. The study highlights concerns about the direct applicability of trial data, particularly for patients with more advanced canc...
Researchers at University of Virginia Health System identify two new cancer-causing gene mutations in MCM8 and MCM9 genes, which may be particularly susceptible to cancer-fighting drugs like cisplatin and olaparib. These mutations could lead to more targeted and effective treatments for lung and prostate cancers.
A study published in the New England Journal of Medicine found that letrozole did not improve pregnancy rates and live birth rates for women with unexplained infertility, but clomiphene remained the best option. Clomiphene enabled production of more eggs and hormones, while gonadotropin had the highest rate of pregnancy and live births.
A new smart lab robot system optimizes cancer treatment by finding the best combination of drugs to kill cancer cells without harming healthy ones. The robot is part of a broader effort to improve cancer treatment research and find new drug compounds for resistant cells.
Researchers have developed a novel type of graphene oxide-based biosensor that can detect biomolecules at a few trillionth of a gram per millimeter square. The sensor's sensitivity is three times higher than commercially available chips, making it ideal for analyzing chemical reactions with small drug molecules.
A combination of two drugs has been found to shrink pancreatic tumors in laboratory mice. The treatment, which targets the cell's DNA rather than proteins, also slowed the growth of human lung cancer cells. Researchers are now working to test this treatment in humans with pancreatic cancer.
Western University researchers have developed an artificial intelligence-powered tool that can predict a patient's response to paclitaxel and gemcitabine chemotherapy medications. The tool uses genetic analysis of tumours to identify the genetic signatures most important for determining resistance and remission for each medication. Wit...
Researchers found a biomarker that can predict which HER2-negative breast cancer patients will respond to bevacizumab treatment, allowing for early switch to more effective options. This discovery could spare patients from severe side effects and improve overall survival rates.
A simple blood test can detect early markers of reinvigorated T cells and track immune responses in metastatic melanoma patients after initial treatment with pembrolizumab. The study found increased levels of proteins characteristic of reinvigoration in CD8+ T cells, suggesting a potential biomarker to predict patient response.
Researchers suggest that combining epigenetic therapies with immunotherapies could restore cell-surface molecules that help the immune system eliminate cancer cells. Epigenetic drugs can also lower or eliminate immune cells that facilitate tumor growth.
Cancer Research UK scientists found that some cancer cells can survive gene damage caused by HDAC inhibitor drugs, triggering a 'survival' response. This mechanism rebalances tags and maintains normal gene activity, making it harder for the drug to kill cancer cells.
Cancer patients who receive chemotherapy treatment for a sustained period have heightened levels of reactive oxygen species (ROS), which correlates with drug resistance. The study proposes a measure of relative ROS levels under normal conditions to help determine if patients are becoming resistant to cancer drugs.
The project aims to create an online cache of molecular data to validate current cancer models and make predictions about the disease. This will enable a collaborative approach to cancer treatment and potentially reduce animal testing in research.
A team of researchers found that inhibiting the enzymatic activity of Tyk2 does not hinder its ability to activate natural killer cells. In fact, this inhibited form of Tyk2 still boosts NK cell maturation and activity, leading to strong suppression of cancer growth. This breakthrough suggests promising potential for new cancer therapies
A chemist at San Diego State University developed a new technique to improve the selectivity of protein kinase inhibitors, which can lead to fewer side effects. By locking in either the right- or left-handed version of an atropisomeric compound, researchers found more selective inhibition of specific kinases.
Researchers have discovered that an anti-diabetic drug can 'suffocate' pancreatic cancer stem cells by preventing them from using oxygen for energy. This finding holds promise for developing new treatments that target these cancer stem cells and prevent recurrence after conventional treatment. Pancreatic cancer remains one of the most ...
Researchers at EMBL-EBI have developed a new computational method to study biological signalling pathways and networks, allowing for more precise questions about how drugs affect proteins and pathways. The method uses noisy data from MS experiment, filters the noise, and integrates the data to reconstruct pathways robustly.
Researchers discovered a new method to attack cancer cells by targeting the SAS1B protein, which appears on cancer cells but not healthy tissue. This approach could lead to reduced side effects and improved fertility preservation for female patients.
Researchers isolated machinery for producing cancer-fighting drug etoposide from endangered Himalayan plant and applied it to a common laboratory plant, producing the chemical. The technique could lead to less expensive and more stable sources of drugs.
A clinical trial using Pembrolizumab plus chemotherapy found the treatment to be safe for patients with advanced small cell and non-small cell lung cancer. The study, led by Dr. Glen Weiss, presented initial results from 12 lung cancer patients enrolled in the 'PembroPlus' clinical trial.
Researchers have found a new strategy to eliminate HIV by reactivating latent infected cells using a class of drugs called Smac mimetics. The approach, which has shown promising results in clinical trials for cancer, may lead to a safe and effective treatment to cure the virus.
A University of Colorado Cancer Center study identified a specific ratio of MET to centromere 7 that defines patients with MET-driven lung cancer susceptible to crizotinib treatment. This threshold has been associated with responses approaching 70 percent in clinical trials.
The study reveals that drugs behave as predicted in the computer-generated model of P-gp, allowing researchers to understand how they bind and inhibit the protein. This breakthrough enables scientists to predict better what will make an inhibitor work, potentially leading to new cancer treatments.
Researchers at UCSF are studying a molecular pathway that underlies many cancers, with the goal of improving diagnosis and treatment. The grant will integrate data from preclinical studies and precision medicine technologies to generate high-resolution molecular information on NF1-associated tumors.
Researchers have found three new drug-like compounds that target a protein responsible for chemotherapy resistance in cancers, offering hope for improved treatment options. The compounds have shown promise in re-sensitizing resistant cancer cells to chemotherapy, improving the odds of survival for prostate cancer patients.
Children's Cancer Institute Australia has been awarded close to $2 million to test new drugs in preclinical models of acute lymphoblastic leukaemia (ALL) under the Pediatric Preclinical Testing Consortium (PPTC). The PPTC will facilitate the acceleration of effective drugs into clinical trials.
Researchers at UC San Diego School of Medicine identified a new pathway that causes resistance to treatments, and developed a therapeutic drug that targets this pathway. The drug, KG5, inhibits the pathway and increases survival rates among patients with aggressive cancers.
Researchers discover that altering protein recycling complexes in human cells enables cancer cells to resist treatment with proteasome inhibitors, a class of drugs used to kill cancer cells. The discovery highlights the potential for targeting this resistant state to develop new cancer treatments.
Researchers at Baylor College of Medicine have discovered a new way to kill cancers driven by the MYC gene, which is responsible for aggressive behavior in many types of malignancies. By inhibiting the spliceosome, a complex machine within cancer cells, scientists can target and destroy tumor cells without harming normal tissues.